Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LPTN has measly 2.36M shares Hyper Tiny OS which is a very rare find!
http://finance.yahoo.com/news/lpath-awarded-department-defense-grant-120200294.html
Nice bounce yesterday! LPTN hit $1.96 again! We should see $2.xx as soon as the coming Monday... Hyper Undervalued now! Hyper Oversold!
Grabbed a few more here today/yesterday. Waiting for catalyst that will see a boom for this sub 2M low floater.
Yes. LPTN has already bottomed out at $1.71 (only total 400 shares manipulated at the Fake 52-week low $1.70) and it is easy double to hit $3.4 again since the Cash Value alone is $2.97 a share...
http://finance.yahoo.com/news/lpath-awarded-department-defense-grant-120200294.html
Tic toc till monster move here in LPTN. Patience will be rewarded imo.
LPTN is up 2.21% so far! $3.71 per share Huge Book Value v.s. at the joke low $1.85 now!
Agreed. Wall Street is the biggest Cesspool in the financial world!
Crime is alive and well and unchallenged in the cesspool that is Wall Street!
LOL, the sick MM just manipulated the price down to the New 52-week low $1.70 today with mere 100 shares! Good luck to you too, bro.!
GL bro! I averaged down to under $2 the last few weeks. Undervalued big time.
I see. I still have a lots of cash available to suck those dirt cheap shares below $1.71 thought I had already bought many shares at $1.7x ~ $1.8x! Any positive news will send this hidden gem back to $3.xx ~ $4.xx again...
Lucky if you have powder bro! I'm tapped out. Awaiting positive news for mega volume and squeeze.
No worry, my friend! I actually hope LPTN to hit another New 52-week low below $1.71 so that all the existing selling pressures could be released at once completely, instead of multiple day's small sales...
With this pathetic low volume substantive news is needed for any substantive move up. These high frequency trades of 100 blocks will not allow any moves up without news. Containment by NASDAQ 'market maker' bots.
IMO, News is not that important for any Hyper Undervalued and Hyper Oversold stock like LPTN since it can naturally bounce once it is bottomed out or the big sellers are gone! Let's see if $1.71 could hold the New bottom support for LPTN... $1.74 is today's low so far!
Miniscule float for sure! Let's have some substantive news and watch this soar!
Yes. LPTN has measly 1.9M shares Hyper Tiny float count which is an Hyper Rare find in the Nasdaq world! Easy double within a day as it did on June 20, 2016 --- see its chart below!
http://finance.yahoo.com/news/lpath-awarded-department-defense-grant-120200294.html
I actually hope the price of LPTN to go down much further (say $1.6x or even $1.5x) so that I can add many many more dirt cheap shares now then I can sell all of them at $2.97 (Cash Value) ~ $3.71 (Book Value) later...
Yep me too. No worries averaging down here. I smell news next week.
Today is an huge loading opportunity to steal those dirt cheap $1.7x shares! I've no any complaint at all!
Yep! I've been quietly loading the last week or so. With 2M low float any positive news kabooms this.
Interest has died on this low floater. Bring on the news and the scalpers will return.
Bring your swingers back and run it up again!
An opportunity for the flippers/shorts? You only show up on the movers..wonder why. Blah blah..support levels..they gotta hold..blah blah. Pft.
* * $LPTN Video Chart 06-20-16 * *
Link to Video - click here to watch the technical chart video
Yup but any grant is a good grant! Shows faith in the science.
SUPER LOW FLOAT!
Nice grant! > Better if it was for $40M+
Could be start of a news blitz post RS! $$$$$$$$$$$$$$$$$$$$$
$3.92~}!!!!!!!!!!!!!!
LPTN
Float has already traded in just 17 minutes! Lol.
Could do bro. Super low 2.5M float now.
Great News. Let's Go LPTN. I see this one going near 5 today.
Great News. Let's Go LPTN. I see this one going to $5 today.
Great News. Let's Go LPTN. I see this one going to $5 today.
YEAH MAN~! LPTN TRADES ON AIR
$3.50 boom!
$3.27 X 3.48
LPTN
Tiny float
nice news=
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20160620:nPnykYdYa
© 2016 InvestorsHub.Com, Inc.
LPTN
News out. $1.45M grant from DMRDP!
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20160620:nPnykYdYa
Didn't they do the 1:14 RS on the 10th June?
Yeah it will be double when they will do R/S
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
712
|
Created
|
11/19/06
|
Type
|
Free
|
Moderators |
![]() | ||||||||||
![]() Lpath Incorporated 4025 Sorrento Valley Blvd. San Diego, CA 92121 Tel: 858-678-0800 FAX: 858-678-0900 | ||||||||||
Lpath, Inc. is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines. | ||||||||||
![]() | ||||||||||
Lpath, Inc. focuses on the discovery and development of monoclonal antibodies that target bioactive lipids. Numerous lipids that contribute to disease have now been identified through the various efforts of academics and industry. However, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2™ platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities. Lpath has leveraged ImmuneY2 and generated monoclonal antibody drug candidates against several bioactive lipids, including sphingosine-1-phosphate (S1P), lysophosphatidic acid (LPA), leukotrienes (LTs) and others. Lpath is currently advancing LpathomabTM, a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has been recognized to be involved in disorders of the central nervous system (including pain, traumatic brain injury, neurodegeneration), fibrosis, ocular disease and cancer. Lpathomab has demonstrated strong preclinical activity in several animal models of these diseases, including neuropathic pain, diabetic neuropathy, traumatic brain injury and spinal cord injury. Lpathomab is currently in a phase 1 clinical trial. The company is applying ImmuneY2 to other bioactive lipid targets, many of which are involved in important disease processes (e.g. inflammation, cancer, pain, asthma, and others) thereby adding to our pipeline of novel antibody-based drug candidates. Lpath has a broad and deep intellectual property position in the bioactive lipid area, with over 50 issued or pending patents in the U.S., with corresponding international applications. Most of these patents were developed in-house using our proprietary technologies and expertise. Executive Team
| ||||||||||
![]() | ||||||||||
Good read: http://seekingalpha.com/article/412101-why-morgan-joseph-expects-triple-digit-gains-for-this-pfizer-partner ASONEP http://www.clinicaltrials.gov/ct2/show/NCT00661414 Share Structure
Transfer Agent(s) |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |